The publicly listed provider of advanced medical technologies and manufacturer of radiopharmaceuticals has accelerated its growth and shifted into high gear. In the third quarter of the financial year 2025, the Synektik Group increased its revenue by 89% to PLN 292.3 million, while generating EBITDA of PLN 71.5 million, 72% higher than in the corresponding period of the previous year. Over the first 9 months of the financial year, the Group’s sales increased by more than half, reaching PLN 733.4 million, resulting in a 55% increase in EBITDA for the period, to nearly PLN 190 million. The Group’s record financial results were driven by stronger sales of medical equipment along with dynamic and consistently expanding recurring revenue across both segments.
Synektik S.A.’s consolidated net income from continuing operations in the third quarter increased by 80% to PLN 55.1 million. The Group’s total net profit for the first 9 months reached PLN 386.4 million, of which nearly PLN 138 million represented profit from continuing operations (a 61% year-on-year increase), while the remaining amount comprised, among other items, the results of the business demerged to Syn2bio.
The Group’s segment focused on advanced medical devices and IT solutions delivered another exceptionally successful period, highlighted by unparalleled sales of medical equipment and record recurring revenue. The latter, generated from the supply of consumables and accessories as well as the provision of services, increased by 26% in the third quarter of this financial year to PLN 103.6 million, and grew by 28% over the first 9 months of this financial year to PLN 291 million. Meanwhile, revenue from medical equipment sales tripled during the past quarter, reaching PLN 175.3 million, and over the first three quarters of the current financial year, it increased by 86% to PLN 401.6 million. Record contract sales and recurring revenue resulted in a doubling of the segment’s total revenue in the third quarter, to PLN 278.9 million, and the generation of PLN 76.1 million in EBITDA (a 78% year-on-year increase) during the period, as well as respective increases of 56% and 57% in revenue (to PLN 692.5 million) and EBITDA (to PLN 197.1 million) over the first 9 months of the financial year 2025.
The radiopharmaceuticals segment generated PLN 13.4 million in revenue in the third quarter of the current financial year (compared with PLN 14.8 million in the corresponding period of the financial year 2024), while delivering a 7% increase in sales to PLN 40.9 million over the first 9 months of the financial year. Sales of proprietary products – core and specialty radiopharmaceuticals supplied under long-term contracts – continue to grow steadily, supporting the expansion of the Group’s recurring revenue. The segment’s EBITDA, at PLN 3.6 million for the third quarter and PLN 12.3 million for the 9-month period, was lower than the results recorded a year earlier, partly due to higher product logistics costs.
“We are concluding yet another period that was both highly intensive and commercially successful, culminating in record financial results. Our sales and operating performance demonstrated over the past 9 months is not only record-breaking but also surpasses our strongest full-year results achieved to date. We are maintaining our momentum and consistently pursuing initiatives to increase the Company’s value in both the short and long term. We entered the final quarter of the year with more than PLN 200 million in backlog and active offers for equipment deliveries, both in Poland and international markets, which we are steadily converting into sales and project execution. In line with our growth strategy, we continue to invest in the product and geographic diversification of our business, which constitute the foundations of the Company’s long-term growth. Already today, more than 20% of the Group’s revenue is generated from international sales. We expect that, through the consistent pursuit of our strategy to develop the Czech and Slovak markets, continued expansion across the Baltic states and the launch of operations in Ukraine in the coming years, we will steadily increase both the value of exports and the share of international sales in the Group’s total revenue,” comments Cezary Kozanecki, CEO and founder of Synektik.
Dariusz Korecki, Vice-President of the Group, emphasizes that the Group’s effective business model enables it to invest simultaneously in business development while sharing the profits generated with shareholders. “Following the disbursement, in the first half of the financial year 2025, of a record dividend of nearly PLN 92 million, at the end of the third quarter we once again reported a cash surplus over interest-bearing liabilities, this time amounting to nearly PLN 36 million. We are investing prudently and consistently in building markets for the Group’s innovative products, advancing our proprietary solutions – including in the field of information technology – while simultaneously pursuing new business opportunities through both organic growth and M&A transactions. We have the organizational, commercial and financial capabilities to remain at the forefront of the technological transformation of healthcare in Central Europe in the years ahead, while steadily increasing the value of Synektik,” says Dariusz Korecki.
